不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Panniculitic primary cutaneous gamma delta T-cell lymphoma with concomitant features of autoimmune disease emphasizing a pathophysiologic continuum of lupus profundus with the panniculitic T cell lymphomas.
Panniculitic primary cutaneous gamma delta T-cell lymphoma with concomitant features of autoimmune disease emphasizing a pathophysiologic continuum of lupus profundus with the panniculitic T cell lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
某些T细胞淋巴瘤表现出肿瘤性淋巴细胞对皮下脂肪的独特归巢特性。T细胞来源的皮下脂膜炎样淋巴瘤主要有两种形式。一种被归类为原发性皮肤γ-δ T细胞淋巴瘤(PGD-TCL),其中脂肪受累占主导,定义了PGD-TCL的脂膜炎样形式。肿瘤细胞属于γ-δ亚群,对CD4和CD8双阴性,和/或可表达CD8。它们通常具有侵袭性临床病程。另一种脂膜炎样T细胞淋巴瘤被归类为皮下脂膜炎样T细胞淋巴瘤(SPTCL)。它代表一种来源于α-β亚群CD8+ T细胞的皮下淋巴瘤,通常具有惰性病程。这两种形式的脂膜炎样T细胞淋巴瘤与深在性红斑狼疮(LP)——一种推测的脂膜炎样T细胞异常增生形式——表现出重叠的组织学特征。
我们分别呈现了三例在红斑狼疮(LE)(两例)和皮肌炎(DM)(一例)背景下发生的脂肪PGD-TCL病例。其中两例的淋巴瘤活检中同时存在LE和DM的特征,而一例既往活检被解读为LP。在后一例中,LP诊断比脂膜炎样PGD-TCL的诊断早了三年。一名诊断为脂膜炎样PGD-TCL的患者在开始他汀类药物治疗后出现了狼疮样综合征,包括某些支持性血清学指标如抗双链DNA抗体,随后发生了噬血细胞综合征。第二名患者表现为PGD-TCL并伴有抗核基质2(NXP2)DM的特征。第三位患者于2003年就诊,表现为LP并覆有急性LE的皮肤特征,初始对Plaquenil有反应,四年后以Plaquenil治疗耐药为先兆被诊断为PGD-TCL。其中两位患者死于其淋巴瘤。
所有活检均显示PGD-TCL的特征性组织病理学。在两例中,PGD-TCL与覆有的LE皮肤表现相关;另一例有淋巴细胞丰富型DM的皮肤改变。在两例中,MXA染色显著阳性,MXA是替代性I型干扰素标志物,通常在LE和DM的活检中上调。此前有八例报道描述了SPTCL伴有LE皮肤改变。在六例中有明确的LE病史,包括初始对Plaquenil有反应的LP,与我们其中一例相似。在SPTCL或脂膜炎性PGD-TCL的背景下,脂膜炎性T细胞淋巴瘤可伴有LE或DM的临床和组织学特征,包括I型干扰素特征上调。识别与这两种原型自身免疫性疾病之一相关的组织学特征,不应被视为排除任何脂膜炎性T细胞淋巴瘤的诊断。LP、SPTCL和脂膜炎性PGD-TCL之间存在临床、组织形态学和病理生理学的连续谱。
Certain T-cell lymphomas exhibit unique homing properties of the neoplastic lymphocytes for the subcutaneous fat. There are two primary forms of subcutaneous panniculitic lymphomas of T-cell origin. One falls under the designation of primary cutaneous gamma-delta T-cell lymphomas (PGD-TCL) whereby there is dominant involvement of the fat defininng a panniculitic form of PGD-TCL. The neoplastic cells are of the gamma-delta subset and are either double negative for CD4 and CD8 and/or can express CD8.
They often have an aggressive clinical course. The other form of panniculitic T-cell lymphoma falls under the designation of subcutaneous panniculitis-like T-cell lymphoma (SPTCL). It represents a subcutaneous lymphoma derived from CD8+ T cells of the alpha-beta subset and typically has an indolent course. These two forms of panniculitic T-cell lymphoma exhibit overlapping histologic features with lupus profundus (LP), a putative form of panniculitic T-cell dyscrasia.
We present three cases of PGD-TCL of the fat in the setting of lupus erythematosus (LE) (two cases) and dermatomyositis (DM) (one case), respectively. There were concurrent features of LE and DM in their lymphoma biopsies in two cases while a prior biopsy in one was interpreted as LP. In this latter case, the LP diagnosis presaged the diagnosis of panniculitic PGD-TCL by three years. One patient diagnosed with panniculitic PGD-TCL had hemophagocytic syndrome after developing a lupus-like complex including certain supportive serologies such as antibodies to double-stranded DNA following initiation of statin therapy. The second patient presented with PGD-TCL and concomitant features of anti-nuclear matrix 2 (NXP2) DM. The third patient presented in 2003 with LP and overlying skin features of acute LE, initially responding to Plaquenil, and then four years later was diagnosed with PGD-TCL heralded by Plaquenil treatment resistance. Two of the patients died of their lymphoma. All biopsies showed a characteristic histopathology of PGD-TCL.
In two cases, the PGD-TCL was associated with overlying LE-cutaneous findings; another case had skin changes of lymphocyte-rich DM. In two cases, the MXA stain was strikingly positive, the surrogate type I interferon marker that is typically upregulated in biopsies of LE and DM. There are eight prior reported cases describing SPTCL with concomitant cutaneous changes of LE. In six cases there was an established history of LE, including LP responding initially to Plaquenil, similar to one of our cases.
In the context of SPTCL or panniculitic PGD-TCL, panniculitic T-cell lymphomas can be associated with concomitant clinical and histologic features of LE or DM, including an upregulated type I interferon signature. Identifying histologic features associated with either of these prototypic autoimmune conditions should not be considered exclusionary to diagnosing any panniculitic T-cell lymphoma. A clinical, histomorphologic, and pathophysiologic continuum exists with LP, SPTCL and panniculitic PGD-TCL.
MEMBER ACCOUNT
登录成功会直接打开下一页。